The relationship between type 2 diabetes (T2D), metformin, and breast cancer is complex. T2D may increase risk, but metformin used as first-line treatment of T2D may decrease breast cancer risk. This comment explores efforts to disentangle effects of T2D and metformin use on breast cancer risk in a prospective study.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W. et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271–281 (2018).
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021).
Kang, C., LeRoith, D. & Gallagher, E. J. Diabetes, obesity, and breast cancer. Endocrinology 159, 3801–3812 (2018).
Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K. et al. Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer 107, 1608–1617 (2012).
Chlebowski, R. T., McTiernan, A., Wactawski-Wende, J., Manson, J. E., Aragaki, A. K., Rohan, T. et al. Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol. 30, 2844–2852 (2012).
Sanderson, M., Lipworth, L., Shrubsole, M. J., Andersen, S. W., Shu, X. O., Zheng, W. et al. Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study. Cancer Causes Control 30, 425–433 (2019).
Goodwin, P. J., Ligibel, J. A. & Stambolic, V. Metformin in breast cancer: time for action. J. Clinical oncol. 27, 3271–3273 (2009).
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269–10273 (2006).
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schunemann, H. J. et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a grade-assessed systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 27, 627–635 (2018).
Park, Y. M., Bookwalter, D. B., O’Brien, K. M., Jackson, C. L., Weinberg, C. R. & Sandler, D. P. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann. Oncol. 32, 351–359 (2021).
Sandler, D. P., Hodgson, M. E., Deming-Halverson, S. L., Juras, P. S., D’Aloisio, A. A., Suarez, L. M. et al. The Sister Study Cohort: baseline methods and participant characteristics. Environ. Health Perspect. 125, 127003 (2017).
Ethics approval and consent to participate
Not applicable. This comment includes published findings from the Sister Study. The Sister Study has been approved by the Institutional Review Board of the NIH. All participants provided written informed consent.
Consent to publish
Data from the Sister Study may be requested following procedures outlined at https://sisterstudy.niehs.nih.gov/English/coll-data.htm.
The authors declare no competing interests.
This work was supported by the Intramural Research Program of the NIH, the National Institute of Environmental Health Sciences (Z01-ES044005 to DPS).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Park, YM.M., Sandler, D.P. Making sense of associations between type 2 diabetes, metformin, and breast cancer risk. Br J Cancer 125, 909–910 (2021). https://doi.org/10.1038/s41416-021-01372-3